Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02048-18. Print 2019 Mar.
Meropenem-vaborbactam is a new agent with the potential to treat carbapenem-resistant (CRE) infections. We describe the activity of meropenem-vaborbactam against representative CRE genotypes and laboratory-engineered isolates harboring mutant genes associated with ceftazidime-avibactam resistance. We also compared disk diffusion and gradient strip testing methods to standard broth microdilution methods. Against 120 CRE isolates, median ceftazidime-avibactam and meropenem-vaborbactam MICs were 1 and 0.03 µg/ml, respectively. Ninety-eight percent (117/120) of isolates were susceptible to meropenem-vaborbactam (MICs ≤ 4 µg/ml). Against isolates harboring mutant , the addition of vaborbactam lowered the meropenem MICs in 78% of isolates (14/18); 100% were susceptible to meropenem-vaborbactam. Median meropenem-vaborbactam MICs were higher against carbapenemase (KPC)-producing isolates with mutant porin genes ( = 26) than against those with wild-type porin genes ( = 54) (0.25 versus 0.03 µg/ml; < 0.0001). Against TOP10 isolates with plasmid constructs containing wild-type or mutant , the addition of vaborbactam at 8 µg/ml lowered the meropenem MICs 2- to 512-fold, resulting in meropenem-vaborbactam MICs of 0.03 µg/ml. The rates of categorical agreement with broth microdilution for disk diffusion or gradient strips ranged from 90 to 95%. Essential agreement rates were higher for research-use-only (RUO) gradient strips manufactured by bioMérieux (82%) than for those manufactured by Liofilchem (48%) (0.0001). Taken together, our data highlight the potent activity of meropenem-vaborbactam against CRE, including isolates resistant to ceftazidime-avibactam. Vaborbactam inhibited both wild-type and variant KPC enzymes. On the other hand, KPC-producing isolates with mutations displayed higher meropenem-vaborbactam MICs than isolates with wild-type The results of susceptibility testing with RUO bioMérieux gradient strips most closely aligned with those of broth microdilution methods.
美罗培南-法硼巴坦是一种新的药物,具有治疗碳青霉烯类耐药(CRE)感染的潜力。我们描述了美罗培南-法硼巴坦对代表性的 CRE 基因型和实验室工程改造的携带与头孢他啶-阿维巴坦耐药相关的突变 基因的分离株的活性。我们还比较了纸片扩散和梯度条测试方法与标准肉汤微量稀释方法。对于 120 株 CRE 分离株,头孢他啶-阿维巴坦和美罗培南-法硼巴坦的中位 MIC 分别为 1 和 0.03μg/ml。98%(117/120)的分离株对美罗培南-法硼巴坦敏感(MICs≤4μg/ml)。对于携带突变 的分离株,添加法硼巴坦使 78%的分离株(14/18)的美罗培南 MIC 降低;所有分离株均对美罗培南-法硼巴坦敏感。产碳青霉烯酶(KPC)的 携带突变 孔蛋白基因的分离株的美罗培南-法硼巴坦 MIC 中位数高于产野生型 孔蛋白基因的分离株( =26)(26)比产野生型 孔蛋白基因的分离株( =54)(0.25 比 0.03μg/ml; <0.0001)。对于含有野生型 或突变 质粒构建体的 TOP10 分离株,添加 8μg/ml 的法硼巴坦可将美罗培南 MIC 降低 2 至 512 倍,导致美罗培南-法硼巴坦 MIC 为 0.03μg/ml。纸片扩散或梯度条与肉汤微量稀释的分类一致性率在 90%至 95%之间。由 bioMérieux 生产的研究用(RUO)梯度条的符合率(82%)高于由 Liofilchem 生产的(48%)(0.0001)。总的来说,我们的数据突出了美罗培南-法硼巴坦对 CRE 的强大活性,包括对头孢他啶-阿维巴坦耐药的分离株。法硼巴坦抑制了野生型和变异型 KPC 酶。另一方面,携带 突变的产 KPC 的 分离株显示出比携带野生型 分离株更高的美罗培南-法硼巴坦 MIC。使用 RUO bioMérieux 梯度条进行药敏试验的结果与肉汤微量稀释方法最接近。